These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26432076)

  • 21. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
    Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
    Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
    Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
    Peggs KS; Mackinnon S
    Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive immunotherapy for cytomegalovirus (CMV) disease in immunocompromised patients.
    Lim JB; Kwon OH; Kim HS; Kim HO; Choi JR; Provenzano M; Stroncek D
    Yonsei Med J; 2004 Jun; 45 Suppl():18-22. PubMed ID: 15250045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
    Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child.
    Iwasenko JM; Scott GM; Ziegler JB; Rawlinson WD
    J Clin Virol; 2007 Oct; 40(2):152-5. PubMed ID: 17698411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategies for the prevention and treatment of cytomegalovirus infection.
    Sellar RS; Peggs KS
    Expert Opin Biol Ther; 2012 Sep; 12(9):1161-72. PubMed ID: 22650422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation.
    Shafat MS; Mehra V; Peggs KS; Roddie C
    Front Immunol; 2020; 11():1694. PubMed ID: 32849591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
    Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y
    Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
    Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
    Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Maffini E; Busca A; Costa C; Giaccone L; Cerrano M; Curtoni A; Cavallo R; Bruno B
    Expert Rev Hematol; 2019 Nov; 12(11):937-945. PubMed ID: 31423858
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
    Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.